Zobrazeno 1 - 10
of 402
pro vyhledávání: '"Bcr abl1"'
Autor:
Funda Ceran, Sema Akıncı, Mehmet Ali Uçar, Gülten Korkmaz, Mehmet Gündüz, Büşranur Çavdarlı, Şule Mine Bakanay, Mesude Falay, Simten Dağdaş, İmdat Dilek, Gülsüm Özet
Publikováno v:
Turkish Journal of Hematology, Vol 39, Iss 3, Pp 196-203 (2022)
Objective: Achieving an early molecular response (EMR) is crucial for improving the prognosis of patients with chronic myeloid leukemia (CML). The halving time (HT) and reduction ratio (RR) of BCR: : ABL1 transcript levels have recently emerged as ad
Externí odkaz:
https://doaj.org/article/9ada105c49da47f79198c8ab6db559d5
Publikováno v:
Turkish Journal of Hematology, Vol 40, Iss 3, Pp 204-205 (2023)
Externí odkaz:
https://doaj.org/article/a655d28af387492a9e4f77542dccd317
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Subhash Varma, Pankaj Malhotra, Parveen Bose, Neelam Varma, Jogeshwar Binota, Dikshat Gopal Gupta, Alka Khadwal, Man Updesh Singh Sachdeva, Preeti Sonam, Ashish Kumar, Shano Naseem, Palak Rana, Minakshi Gupta, Amita Trehan
Publikováno v:
Leukemia & Lymphoma. 63:633-643
For the detection of BCR-ABL1-like ALL cases, two methodologies, specifically Gene expression profiling (GEP) or Next-generation targeted sequencing (NGS) and TaqMan based low-density (TLDA) card, are being used. NGS is very costly and TLDA is not wi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::76684034d2b79bb78c63040962cfb657
https://doi.org/10.1080/10428194.2021.1999439
https://doi.org/10.1080/10428194.2021.1999439
Autor:
Rosandra N. Kaplan, Olga Kim, Alice Ranjan, Martha Quezado, Jing Wu, Mythili Merchant, Liqiang Xi, Guangyang Yu, Megan Mackey, Kevin Camphausen, Matthias Holdhoff, Young K. Song, Zied Abdullaev, Kenneth Aldape, Kareem A. Zaghloul, David O. Kamson, Jun Wei, Terri S. Armstrong, Javed Khan, Sivasish Sindiri, Xinyu Wen, Ying Pang, Mark R. Gilbert, Svetlana Pack, Lisa Boris, Madison Butler, Ramya Antony, Orwa Aboud, Hsien-Chao Chou
Publikováno v:
JCO Precis Oncol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0eb3dcacdaf2d81eb31a6f44825849a4
https://doi.org/10.1200/po.20.00519
https://doi.org/10.1200/po.20.00519
Publikováno v:
Case Reports in Oncology
Case Reports in Oncology, Vol 14, Iss 3, Pp 1707-1711 (2021)
Case Reports in Oncology, Vol 14, Iss 3, Pp 1707-1711 (2021)
Quantitative PCR-based strategies are typically effective for monitoring BCR-ABL1 transcript levels in chronic myeloid leukemia (CML). Additionally, some patients treated with tyrosine kinase inhibitors can experience long-term treatment-free remissi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a11e23445e702af9edb4d5b5883c2c15
http://europepmc.org/articles/PMC8740187
http://europepmc.org/articles/PMC8740187
Autor:
Hristo J. Ivanov, Zhanet Grudeva-Popova, Ivan Zheljazkov, Alexander Linev, Vily Stoyanova, Veselina Goranova-Marinova
Publikováno v:
Folia Medica, Vol 63, Iss 5, Pp 670-675 (2021)
Introduction: The T315I mutation in patients with chronic myeloid leukemia (CML) has been associated with therapeutic resistance and an unfavourable prognosis. Aim: To study the frequency of T315I mutation in patients with CML, BCR-ABL(+), their clin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e74d5b0b55f8e0a9019a9439b466eed7
https://doi.org/10.3897/folmed.63.e63366
https://doi.org/10.3897/folmed.63.e63366
Publikováno v:
Expert Review of Hematology. 14:975-978
Chronic myeloid leukemia (CML) results from the reciprocal translocation between the long arms of chromosomes 9 and 22. The translocation, t(9;22)(q34;q11.2) is referred to as the Philadelphia chro...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0b1e30b7603ca75d57fc8b5431f2baef
https://doi.org/10.1080/17474086.2021.1990034
https://doi.org/10.1080/17474086.2021.1990034
Autor:
Emmanuelle Clappier, Hélène Cavé, Philippe Kastner, Chloé Arfeuille, Célestine Simand, Beate Heizmann, Aurélie Caye, Rathana Kim, Susan Chan, Marie Passet, Céline Keime
Publikováno v:
Haematologica
Haematologica, 2021, 107 (1), pp.316-320. ⟨10.3324/haematol.2021.279125⟩
Haematologica, 2021, 107 (1), pp.316-320. ⟨10.3324/haematol.2021.279125⟩
Not available.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9650ddeb10c55b6c82fc5042d154e9bc
https://doi.org/10.3324/haematol.2021.279125
https://doi.org/10.3324/haematol.2021.279125
Autor:
Siong Leng Hon, Rui Jeat Fann, Tze Shin Leong, Sen Mui Tan, Asral Wirda Ahmad Asnawi, Siew Lian Chong, Kian Boon Law, Jenq Tzong Tan
Publikováno v:
Blood research
Background With the emergence of tyrosine kinase inhibitors and the incorporation of stringent measurable residual disease (MRD) monitoring, risk stratification for BCR-ABL1-positive acute lymphoblastic leukemia (ALL) patients has changed significant
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cd1d82070b69312b2befcd48351bba1b
http://europepmc.org/articles/PMC8478615
http://europepmc.org/articles/PMC8478615